
Lilly (LLY) Phase III Study in Ulcerative Colitis Meets Goal
Published on December 15, 2021
Eli Lilly's (LLY) mirikizumab meets primary and key secondary endpoints in a phase III maintenance study in ulcerative colitis.

Eli Lilly's (LLY) mirikizumab meets primary and key secondary endpoints in a phase III maintenance study in ulcerative colitis.